Soley focusing on the blood levels of these proteins may confound how the response to AD therapies, such as with anti-amyloid and potentially anti-tau antibodies, is interpreted; ideally, blood biomarkers that are not targets of such therapies should be used to monitor for therapy effects. The gene discussed is MAPT; the disease is Alzheimer disease.